Key takeaways
- “Copper peptides” covers more than one molecule: GHK-Cu (copper tripeptide-1), AHK-Cu and a code-named research peptide; one hair trial used GHK without copper.
- The only placebo-controlled study of a GHK-Cu serum we found was in the eyebrows of 18 healthy adults, published in conference proceedings in 2026.
- Every other human study we found used GHK without copper, combined a copper peptide with other actives or drugs, or had no control group; we found no copper-peptide hair study on ClinicalTrials.gov.
- In the US, a claim that a product will restore hair growth makes it a drug, and non-prescription hair growers need an approved application.
- FDA-approved medicines for pattern hair loss include topical minoxidil and prescription finasteride; no GHK-Cu medicine appears in Drugs@FDA.
01Copper peptides and hair at a glance
Hair studies only, dated 18 November 2026. The compound’s wider research is on the GHK-Cu research guide, its skin studies on topical GHK-Cu, and peptides in creams and serums generally on peptides in skincare.
| Question | Copper peptides and hair |
|---|---|
| What “copper peptides” means | Short peptides bound to copper. The best known is GHK-Cu, the copper complex of glycyl-histidyl-lysine, listed in cosmetics as copper tripeptide-1. Hair research has also used AHK-Cu, a different copper tripeptide, and GHK without copper. |
| Human evidence for hair | T1, small: one randomised eyebrow study of a GHK-Cu serum in 18 healthy adults, in conference proceedings. Other human studies, some of them large, tested formulations or procedures in which a copper peptide was one of several actives, so they cannot isolate its effect. |
| Animal and lab evidence | T3/T4: rats (1993), mice (1991, known to us only by its title), and human hair follicles kept alive in the lab (2007, AHK-Cu). |
| Registered studies | None of a copper peptide for hair on ClinicalTrials.gov (searched 18 Nov 2026). |
| FDA-approved medicines for pattern hair loss | These include topical minoxidil (first approved 1988, now over the counter) and finasteride tablets (Propecia, approved 1997, prescription). |
| US rule | A claim that a product will restore hair growth makes it a drug. No GHK-Cu medicine appears in Drugs@FDA. |
| United Kingdom | UK law treats a product given to restore, correct or modify physiological functions through a pharmacological, immunological or metabolic action as a medicine; the MHRA’s guidance cites a 1991 European court ruling on minoxidil sold as a cosmetic. |
| Australia | The Poisons Standard lists minoxidil in Schedule 2 or 4 and finasteride in Schedule 4. |
02Which hair studies used copper peptides, and what did they measure?
Every study we found that tested a copper peptide, or GHK, on hair or hair follicles, except one family of clinic formulations described below the table. We report design and measures, not the authors’ conclusions.
| Study | Model and design | What it tested | What was measured |
|---|---|---|---|
| Trachy et al., 1991 | C3H mice; a one-page conference report co-authored by Loren Pickart, who isolated GHK from human plasma in 1973 | “Peptide copper complexes” | Known to us only by its title |
| Uno and Kurata, 1993 | Fuzzy rats, back skin, within a review of the authors’ animal work | A copper-binding peptide coded PC1031 (sequence not given in the abstract), alongside topical minoxidil | Hair follicle size |
| Pyo et al., 2007 | Human hair follicles kept alive outside the body, and cultured dermal papilla cells | AHK-Cu, a copper tripeptide with alanine in place of glycine | Follicle elongation, cell growth, markers of cell death |
| Lee et al., 2016 | Randomised, double-blind, placebo-controlled, 6 months; 45 men with male pattern hair loss | GHK chemically joined to 5-aminolevulinic acid, without copper | Hair count, length and thickness; satisfaction; adverse events |
| Bertin et al., 2018 | Four case reports, no control group | Laser treatment followed by topical finasteride, growth factors and a copper peptide | Photographs |
| Patel et al., 2024 | Open-label, single group, 15 days; 32 adults with dandruff enrolled, 29 completed; one author employed by the manufacturer | A scalp scrub and a serum with copper tripeptide-1, witch hazel, hesperidin, hyaluronic acid and pea protein | Flaking, scalp hydration, hair density and thickness by imaging |
| Kuceki et al., 2025 | Retrospective review of 7 men with pattern hair loss; photographs rated blind | A clinic procedure combining minoxidil, dutasteride and copper peptides, with topical minoxidil continued | Scalp coverage, rated by four dermatologists and an AI tool |
| Bo et al., 2026 | Randomised, double-blind, split-face: one eyebrow with a GHK-Cu serum, the other with a placebo serum; 12 weeks; 18 healthy adults aged 18 to 40; conference proceedings | GHK-Cu serum | Eyebrow hair count and diameter, photo scores, satisfaction, adverse effects |
Not in the table: QR678, a clinic-administered formulation whose published composition lists copper tripeptide-1 alongside several growth factors and other peptides. Authors from one clinic group in Mumbai have reported studies of it in hair loss since 2018, including a single-arm study of 1,000 patients; later studies compared it, or a variant whose copper content is not stated, with other treatments. With that many active ingredients, these studies cannot show anything about a copper peptide on its own.
Only the 2026 eyebrow study compares a GHK-Cu serum with a placebo, and it was in the eyebrows of healthy adults, not in scalp hair loss. Every other human study combined a copper peptide with other active ingredients or drugs, used GHK without copper, or had no control group. The animal and lab work used two other peptides, PC1031 and AHK-Cu, or is known only by its title.
03What do independent reviews say about copper peptides and hair?
Two 2026 reviews reach the question from different sides.
An evidence map of GHK-Cu. Mateescu and colleagues, in Pharmaceutics, found that its clinical evidence “remains sparse and does not meet contemporary active-entity quality standards”, a standard the authors define around characterising the exact chemical form that was tested. They describe the eyebrow study as “a small single-center study with a cosmetic endpoint and chemically undercharacterized test material”.
A systematic review of peptides for hair loss. Joerg and colleagues, in the Journal of Drugs in Dermatology, included 14 clinical trials of peptide-containing treatments, searching to November 2025. Its abstract does not say whether any included trial used GHK bound to copper or tested a copper peptide on its own, and we could not read the full text.
We found no large trial of GHK-Cu on its own for scalp hair loss for either review to rest on. How we grade evidence: evidence grades.
04Is a copper-peptide hair product a cosmetic or a drug?
United States. FDA decides whether a product is a cosmetic or a drug by its intended use, and claims count. Among its examples of claims that make a product a drug “even if the product is marketed as if it were a cosmetic”, FDA lists claims that products “will restore hair growth”. A 1989 federal rule goes further for products sold without a prescription: any product “labeled, represented, or promoted for external use as a hair grower or for hair loss prevention” is regarded as a new drug that needs an approved application (21 CFR 310.527). The same rule records “a lack of adequate data to establish general recognition of the safety and effectiveness” of any ingredient for that use.
The medicines FDA has approved for pattern hair loss include topical minoxidil, first approved in 1988 and now sold over the counter with the label purpose “Hair regrowth treatment”, and finasteride (Propecia), a prescription tablet approved in 1997 and indicated for male pattern hair loss “in MEN ONLY”. No medicine containing GHK-Cu appears in Drugs@FDA.
United Kingdom. UK law defines a cosmetic by its purpose on the outside of the body, including the hair, and the MHRA applies medicines tests to borderline products. Its guidance note on what counts as a medicine summarises a 1991 ruling of the European Court of Justice on minoxidil sold as a cosmetic (Upjohn v Farzoo, C-112/89): male pattern baldness was not a disease, but a product is still a medicine if it is administered “with a view to ... restoring, correcting or modifying physiological functions”.
Australia. The Poisons Standard October 2026 lists minoxidil in Schedule 2 (pharmacy medicine) for skin preparations up to a set strength and in Schedule 4 (prescription only) otherwise, and finasteride in Schedule 4. We have not verified how Australian rules treat a cosmetic containing GHK-Cu.
05What we don’t know about copper peptides and hair
- Whether GHK-Cu on its own changes scalp hair in people with hair loss. We found no published controlled trial of it alone, and no registered copper-peptide hair study on ClinicalTrials.gov (PubMed and ClinicalTrials.gov, 18 Nov 2026).
- What the early animal work tested. The 1991 report is known to us only by its title, and the 1993 abstract does not give PC1031’s sequence.
- How much intact GHK-Cu reaches a hair follicle from a product. None of the human hair studies above reports measuring it.
- Long-term effects. The two placebo-controlled studies in the table ran for 12 weeks (eyebrows, 18 people) and 6 months (scalp, 45 men, GHK without copper).
- Anything about injected GHK-Cu on its own, a different route with no controlled human data that we found: see topical GHK-Cu.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.